Products with Activators bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2183 | Ramelteon |
| 1. Ramelteon significantly improves symptoms in patients with gastroesophageal reflux disease and significantly improves patients' sleep experience. 2. Ramelteon could be a potential therapeutic drug, in adjunctive treatment of learning and memory deficits seen in patients with schizophrenia. 3. Ramelteon is effective for the prevention of delirium, ramelteon administered nightly to elderly patients admitted for acute care may provide protection against delirium. 4. Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment, demonstrates no significant effects indicative of potential for abuse or motor and cognitive impairment at up to 20 times the recommended therapeutic dose. | |
| BCN2237 | Estriol 17-sulfate |
| 1. Estriol 17-sulfate stimulates PR very significantly in the MCF-7 human mammary cancer cell line E3 and E3-3-S. | |
| BCN2355 | Cucurbitacin D |
| Cucurbitacin D has anticancer effects, it induces apoptosis through caspase-3 and phosphorylation of JNK in hepatocellular carcinoma cells. Cucurbitacin D may be a potential therapeutic agent for β-hemoglobinopathies, including sickle cell anemia and β-thalassemia. Cucurbitacin D is a new inflammasome activator in macrophages, it can initiate immunomodulating activity in macrophages to lead to inflammasome activation as well as enhancement of LPS signaling. | |
| BCN2476 | Dihydromethysticin |
| 1. The induction of CYP3A23 by dihydromethysticin and desmethoxyyangonin involves transcription activation, probably through a pregnane X receptor (PXR).-independent or PXR-involved indirect mechanism. 2. Dihydromethysticin non-competitively inhibits the specific binding of [3H]-batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltage-gated Na+ channels. | |
| BCN2539 | Pterostilbene |
| Pterostilbene acts as a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, it has been implicated in anticarcinogenesis, antioxidant, modulation of neurological disease, anti-inflammation, attenuation of vascular disease, and amelioration of diabetes. Pterostilbene downregulates inflammatory iNOS and COX-2 gene expression in macrophages by inhibiting the activation of NFkappaB by interfering with the activation of PI3K/Akt/IKK and MAPK. Pterostilbene may protect HUVECs against oxLDL-induced apoptosis by downregulating LOX-1-mediated activation through a pathway involving oxidative stress, p53, mitochondria, cytochrome c and caspase protease. | |
